Fig. 1: Survival after CART exposure.

PFS after CART exposure in DHL vs non-DHL (A) and DHL vs DEL vs other (B). OS after CART exposure in DHL vs non-DHL (C) and DHL vs DEL vs other (D). CART chimeric antigen receptor T-cell therapy, DEL double expressor lymphoma, DHL double hit lymphoma, Mon months, No number, OS overall survival, PFS progression- free survival.